{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(1)"],"submitter":["Lapteva M"],"pubmed_abstract":["Monoclonal antibodies targeting cytokines are administered parenterally for the systemic treatment of severe psoriasis. However, systemic exposure to the biologic increases the risk of side-effects including immunosuppression, whereas only a small fraction of the active molecules actually reaches the target organ, the skin. This preclinical study examines the feasibility of delivering a humanized anti-CD29 monoclonal antibody (OS2966) topically to skin using minimally-invasive fractional laser ablation. This approach would enable the targeted use of a biologic for the treatment of recalcitrant psoriatic plaques in patients with less widespread disease while minimizing the risk of systemic exposure. First, the effect of a wide range of laser poration conditions on skin permeation and deposi"],"journal":["Scientific reports"],"pagination":["1030"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6355906"],"repository":["biostudies-literature"],"pubmed_title":["Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody - OS2966."],"pmcid":["PMC6355906"],"pubmed_authors":["Lapteva M","Kalia YN","Wu E","Del Rio-Sancho S","Bohler C","Carbonell WS"],"additional_accession":[]},"is_claimable":false,"name":"Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody - OS2966.","description":"Monoclonal antibodies targeting cytokines are administered parenterally for the systemic treatment of severe psoriasis. However, systemic exposure to the biologic increases the risk of side-effects including immunosuppression, whereas only a small fraction of the active molecules actually reaches the target organ, the skin. This preclinical study examines the feasibility of delivering a humanized anti-CD29 monoclonal antibody (OS2966) topically to skin using minimally-invasive fractional laser ablation. This approach would enable the targeted use of a biologic for the treatment of recalcitrant psoriatic plaques in patients with less widespread disease while minimizing the risk of systemic exposure. First, the effect of a wide range of laser poration conditions on skin permeation and deposi","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2026-05-06T21:50:54.231Z","creation":"2019-03-26T22:47:52Z"},"accession":"S-EPMC6355906","cross_references":{"pubmed":["30705293"],"doi":["10.1038/s41598-018-36966-0"]}}